These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34151896)

  • 1. Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States.
    Sussell J; Singh Jhuti G; Antao V; Herrera-Restrepo O; Wehler E; Bilir SP
    Am J Clin Oncol; 2021 Jul; 44(7):340-349. PubMed ID: 34151896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
    Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
    JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada.
    Younis T; Lee A; Coombes ME; Bouganim N; Becker D; Revil C; Jhuti GS
    Curr Oncol; 2020 Dec; 27(6):e578-e589. PubMed ID: 33380873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
    N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
    Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A
    Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
    Huang CS; Yang Y; Kwong A; Chen SC; Tseng LM; Liu MC; Shen K; Wang S; Ng TY; Feng Y; Sun G; Yan IR; Shao Z
    Breast Cancer Res Treat; 2021 Jun; 187(3):759-768. PubMed ID: 33860389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
    Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
    J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.
    Lyseng-Williamson KA
    Drugs; 2020 Nov; 80(16):1723-1730. PubMed ID: 32996066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Conte P; Schneeweiss A; Loibl S; Mamounas EP; von Minckwitz G; Mano MS; Untch M; Huang CS; Wolmark N; Rastogi P; D'Hondt V; Redondo A; Stamatovic L; Bonnefoi H; Castro-Salguero H; Fischer HH; Wahl T; Song C; Boulet T; Trask P; Geyer CE
    Cancer; 2020 Jul; 126(13):3132-3139. PubMed ID: 32286687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
    Williamson M; Press DJ; Hansen SA; Tomar A; Jhuti GS; Revil C; Gururaj K
    Breast Cancer; 2024 Jan; 31(1):84-95. PubMed ID: 37907759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
    Mamounas EP; Untch M; Mano MS; Huang CS; Geyer CE; von Minckwitz G; Wolmark N; Pivot X; Kuemmel S; DiGiovanna MP; Kaufman B; Kunz G; Conlin AK; Alcedo JC; Kuehn T; Wapnir I; Fontana A; Hackmann J; Polikoff J; Saghatchian M; Brufsky A; Yang Y; Zimovjanova M; Boulet T; Liu H; Tesarowski D; Lam LH; Song C; Smitt M; Loibl S
    Ann Oncol; 2021 Aug; 32(8):1005-1014. PubMed ID: 33932503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model.
    Hendrix N; Oestreicher N; Lalla D; Dolan CM; Fisher KA; Veenstra DL; Moy B
    Clin Breast Cancer; 2022 Dec; 22(8):781-791. PubMed ID: 36220724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
    Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
    Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
    Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
    BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer.
    Delgado J; Vleminckx C; Sarac S; Sosa A; Bergh J; Giuliani R; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100074. PubMed ID: 33647599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.
    Magalhães Filho MAF; Aguiar PN; Neves MBM; Lopes GL; Del Giglio A
    Einstein (Sao Paulo); 2022; 20():eGS6655. PubMed ID: 35544899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.